Medpace Holdings, Inc.: directors' dealings · United States · SEC (Form 4)

About Medpace Holdings, Inc.

Medpace Holdings, Inc. (ticker: MEDP) is a U.S.-listed company trading on the NASDAQ in the United States. For equity investors, Medpace is best understood as a high-science healthcare services business rather than a drug developer: it is a full-service clinical contract research organization (CRO) that supports biotechnology, pharmaceutical, and medical device sponsors across the full clinical development cycle, from Phase I through Phase IV. Its integrated model spans clinical operations, project management, regulatory consulting, data management, biostatistics, central laboratory services, imaging, bioanalytical testing, and cardiac safety capabilities. ([investor.medpace.com](https://investor.medpace.com/?utm_source=openai)) The company was founded in 1992 in Cincinnati, Ohio, by Dr. August J. Troendle, who remains CEO and Chairman. Medpace’s global headquarters is still based in Cincinnati, United States, where the company has built a large clinical research campus and key shared-service infrastructure. Over time, Medpace has expanded well beyond its U.S. base into Europe, Asia-Pacific, Latin America, and other regions, with office and laboratory locations across six continents. That geographic footprint is strategically important in modern clinical development, where sponsors need access to patients, local regulatory knowledge, and cross-border execution capabilities. ([medpace.com](https://www.medpace.com/careers/about-medpace/?utm_source=openai)) Medpace’s competitive positioning is centered on a disciplined, single-vendor, full-service operating model. The company emphasizes scientific depth and therapeutic specialization, aiming to simplify outsourcing for clients that want one coordinated partner rather than a fragmented vendor network. Its owned laboratory and early-phase assets are a key differentiator: Medpace highlights wholly owned central labs, a bioanalytical lab, an imaging core lab, an ECG core lab, and a Phase I Unit in Cincinnati. The company also markets capabilities across several important therapeutic areas, including oncology, cardiology, metabolic disease, endocrine disorders, central nervous system conditions, antiviral and anti-infective programs, and newer crossover areas such as cell and gene therapy. ([medpace.com](https://www.medpace.com/?utm_source=openai)) From a market perspective, Medpace operates in a highly competitive global CRO industry, where scale, regulatory expertise, patient access, and operational consistency are critical. Its niche is not “lowest-cost outsourcing”; rather, Medpace is positioned as a scientifically driven partner for complex trials, especially for biotech clients that value speed, quality, and close study oversight. This positioning can support pricing power and margin resilience when execution is strong, although the business remains exposed to sponsor funding cycles and trial start timing. ([medpace.com](https://www.medpace.com/?utm_source=openai)) Recent developments underscore the company’s momentum. In the first quarter of 2026, Medpace reported revenue of $706.6 million, up 26.5% year over year, with net new business awards of $618.4 million and backlog of $2.93 billion at March 31, 2026. Management also reaffirmed full-year 2026 revenue guidance of $2.755 billion to $2.855 billion. In addition, the company disclosed that President Jesse Geiger intends to retire effective May 31, 2026, with CEO August Troendle temporarily reassuming the president role. For investors, Medpace currently combines strong operating execution, a sizeable backlog, and a clearly defined niche in the NASDAQ-listed U.S. healthcare services universe. ([investor.medpace.com](https://investor.medpace.com/news-releases/news-release-details/medpace-holdings-inc-reports-first-quarter-2026-results/?utm_source=openai))